Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Evaluate Vantage Homepage
  3. Pharmaceutical Companies
  4. Fortress Biotech
Thumbnail
February 11, 2022

How China applicants could avoid the sintilimab scenario

A US adcom savages sintilimab, but the biggest problems identified might be sintilimab-specific.

Thumbnail
January 25, 2022

Checkpoint's low-cost oncology project inches towards the market

Article image
Vantage logo
September 29, 2021

Crucial clinical events for the smaller players

Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.

Article image
Vantage logo
September 29, 2021

Non-genetic amyloidosis lives again, thanks to Darzalex and Astra

Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.

Article image
Vantage logo
June 25, 2021

No fast way to eighth place for Incyte

Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?

Article image
Vantage logo
June 22, 2021

EQRX vows to slash drug prices where others have failed

Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.

Article image
Vantage logo
November 02, 2020

US FDA approval tracker: October

Article image
Vantage logo
July 07, 2020

Another clinical hold for Cellectis

Article image
Vantage logo
March 26, 2020

Biotech’s balancing act amid Covid-19 delays

A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.

Article image
Vantage logo
July 18, 2019

Servier leaves Macrogenics again

Article image
Vantage logo
June 06, 2019

Takeda casts doubt on the remaining approach to amyloidosis

After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.